Min‐Hee Ryu

20.0k total citations · 3 hit papers
327 papers, 7.6k citations indexed

About

Min‐Hee Ryu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Min‐Hee Ryu has authored 327 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 228 papers in Pulmonary and Respiratory Medicine, 150 papers in Oncology and 116 papers in Gastroenterology. Recurrent topics in Min‐Hee Ryu's work include Gastric Cancer Management and Outcomes (194 papers), Gastrointestinal Tumor Research and Treatment (115 papers) and Colorectal Cancer Treatments and Studies (74 papers). Min‐Hee Ryu is often cited by papers focused on Gastric Cancer Management and Outcomes (194 papers), Gastrointestinal Tumor Research and Treatment (115 papers) and Colorectal Cancer Treatments and Studies (74 papers). Min‐Hee Ryu collaborates with scholars based in South Korea, United States and Japan. Min‐Hee Ryu's co-authors include Yoon‐Koo Kang, Baek‐Yeol Ryoo, Jae‐Lyun Lee, Tae Won Kim, Heung Moon Chang, Hyun Cheol Chung, Changhoon Yoo, Jeong Hwan Yook, Yung‐Jue Bang and Young Soo Park and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Min‐Hee Ryu

307 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

2020 802 citations Kohei Shitara, Yung‐Jue Bang et al. profile →
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

2018 372 citations Lucjan Wyrwicz, Min‐Hee Ryu et al. Annals of Oncology profile →
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

2018 228 citations Min‐Hee Ryu, Hyun Cheol Chung et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Min‐Hee Ryu

Since Specialization

Citations

This map shows the geographic impact of Min‐Hee Ryu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min‐Hee Ryu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min‐Hee Ryu more than expected).

Fields of papers citing papers by Min‐Hee Ryu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min‐Hee Ryu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min‐Hee Ryu. The network helps show where Min‐Hee Ryu may publish in the future.

Co-authorship network of co-authors of Min‐Hee Ryu

This figure shows the co-authorship network connecting the top 25 collaborators of Min‐Hee Ryu. A scholar is included among the top collaborators of Min‐Hee Ryu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min‐Hee Ryu. Min‐Hee Ryu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results 2024 ·Annals of Oncology ·(unknown), D-Y. Oh, Min‐Hee Ryu, Emiliano Calvo, (unknown), (unknown), (unknown), (unknown), Özlem Yıldırım, Serena Masciari, Gu Mi, (unknown), Pınar Kanlikilicer, (unknown), Faı̈za Rharbaoui, Giovanni Abbadessa, Ecaterina E. Dumbrava	0
2	Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer 2024 ·Gastric Cancer ·(unknown), (unknown), Heejung Chae, Young Soo Park, Min‐Hee Ryu, Hyung‐Don Kim, Yoon‐Koo Kang	1
3	Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs) 2024 ·BMC Cancer ·(unknown), Hyung‐Don Kim, (unknown), Min‐Hee Ryu, Yoon‐Koo Kang	0
4	Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy 2024 ·Gastric Cancer ·Hyung‐Don Kim, Jinho Shin, In Hye Song, Jaewon Hyung, (unknown), Min‐Hee Ryu, Young Soo Park	7
5	A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. 2024 ·Journal of Clinical Oncology ·Ronan J. Kelly, (unknown), Kensei Yamaguchi, (unknown), Toshihiro Kudo, Zev A. Wainberg, Sun Young Rha, Jeeyun Lee, Min‐Hee Ryu, (unknown), Kohei Shitara	2
6	Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study. 2024 ·Journal of Clinical Oncology ·Sun Young Rha, Lucjan Wyrwicz, (unknown), Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, M. Fernández, Jin Li, Maeve A. Lowery, Timuçin Çil, Felipe José Silva Melo Cruz, Do‐Youn Oh, Lina Yin, Sonal Bordia, Pooja Bhagia, Shukui Qin	5
7	Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial 2024 ·Nature Medicine ·Hyung‐Don Kim, (unknown), Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, (unknown), Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo	29
8	SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review 2024 ·Gastric Cancer ·(unknown), Hyung‐Don Kim, Min‐Hee Ryu, Young Soo Park	3
9	Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions 2023 ·Gastric Cancer ·Yoon‐Koo Kang, Hyung‐Don Kim, Hyun Jin Kim, Young Soo Park, (unknown), Min‐Hee Ryu	2
10	O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer 2023 ·Annals of Oncology ·Lucjan Wyrwicz, Do‐Youn Oh, (unknown), Yuxian Bai, Min‐Hee Ryu, (unknown), Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, (unknown), J. Li, (unknown), (unknown), (unknown), Shukui Qin, Lei Yin, Sonal Bordia, Pooja Bhagia, Sun Young Rha	3
11	Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens 2023 ·Cancer Research Communications ·Josep Tabernero, Philippe L. Bédard, Yung‐Jue Bang, María Vieito, Min‐Hee Ryu, (unknown), Mustapha Chadjaa, Christine Soufflet, (unknown), Anas Gazzah	9
12	Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial 2022 ·Journal of Clinical Oncology ·Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min‐Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun‐Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, (unknown), Masahiro Sugihara, Kohei Shitara	76
13	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study 2021 ·Liver Cancer ·Changhoon Yoo, Jwa Hoon Kim, Min‐Hee Ryu, Sook Ryun Park, Danbi Lee, Kang Mo Kim, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Joycelyn Jie Xin Lee, David Tai, Stephen L. Chan, Baek‐Yeol Ryoo	68
14	Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma 2021 ·Liver International ·Won‐Mook Choi, Ji Yoon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Min‐Hee Ryu, Baek‐Yeol Ryoo, Kang Mo Kim	28
15	The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene 2020 ·Biochemical and Biophysical Research Communications ·(unknown), Young‐Kyoung Shin, (unknown), Min‐Hee Ryu, Ja‐Lok Ku, Yoon‐Koo Kang	9
16	Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma 2020 ·Hepatology Communications ·Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, (unknown), Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim	35
17	Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression 2015 ·BMC Cancer ·Ji Hyun Park, Min‐Hee Ryu, Young Soo Park, Sook Ryun Park, (unknown), (unknown), Yoon‐Koo Kang	24
18	Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib 2010 ·Journal of Clinical Oncology ·Changhoon Yoo, Min‐Hee Ryu, Byung Woog Kang, Shinkyo Yoon, Baek‐Yeol Ryoo, Heung-Moon Chang, Jae‐Lyun Lee, (unknown), (unknown), Yoon‐Koo Kang	73
19	Survival according to Treatment Modalities in 137 Patients with Aplastic Anemia 2003 ·Blood Research ·Hee-Jung Sohn, (unknown), (unknown), (unknown), (unknown), Eun-Kyung Kim, Gyeong‐Won Lee, Jae‐Lyun Lee, Min‐Hee Ryu, Seong‐Jun Choi, Je‐Hwan Lee, Sung‐Bae Kim, Sang‐We Kim, Kyoo‐Hyung Lee, Jung‐Shin Lee, Woo-Kun Kim, Cheolwon Suh	0
20	A Case of Chylous Ascites Associated with Non-Hodgkin's Lymphoma and Liver Cirrhosis 2002 ·Blood Research ·(unknown), Min‐Hee Ryu, (unknown), (unknown), Heung-Moon Chang, Tae‐Won Kim, Jung‐Shin Lee, (unknown), Yoon‐Koo Kang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact